362 related articles for article (PubMed ID: 17898658)
21. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Else LJ; Jackson V; Brennan M; Back DJ; Khoo SH; Coulter-Smith S; Lambert JS
HIV Med; 2014 Nov; 15(10):604-10. PubMed ID: 24825070
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
23. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
24. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
25. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
Gianotti N; Soria A; Lazzarin A
New Microbiol; 2007 Apr; 30(2):79-88. PubMed ID: 17619250
[TBL] [Abstract][Full Text] [Related]
26. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
27. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
[TBL] [Abstract][Full Text] [Related]
33. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
35. HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
Nso Roca AP; Larru B; Bellón JM; Mellado MJ; Ramos JT; González MI; Navarro ML; Muñoz-Fernández MÁ; José MI
J Adolesc Health; 2011 Jan; 48(1):100-2. PubMed ID: 21185531
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
37. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
[TBL] [Abstract][Full Text] [Related]
38. [Clinical utility of atazanavir].
Ribera Pascuet E; Curran A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
[TBL] [Abstract][Full Text] [Related]
39. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
[TBL] [Abstract][Full Text] [Related]
40. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
